Actavis (ACT) Reports In-Line Q4 EPS; Guides FY15 EPS, Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Actavis (ACT) PT Lifted to $340 at Argus
February 20, 2015 9:32 AM ESTArgus reiterated a Buy rating and boosted its price target on Actavis (NYSE: ACT) to $340.00 (from $310.00), noting the company is gnerating strong growth, while also preparing for the Allergan acquisition.
The firm is boosting 2015 stand-alone adj-EPS from $16.55 to $16.80, indicating 20% growth. The stock... More
Actavis (ACT) PT Lifted to $345 at Guggenheim Following Q4 Results and Update
February 18, 2015 4:23 PM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Actavis (NYSE: ACT) to $345.00 (from $300.00) following Q4 results and outlook.
Chen comments, "We are raising our PT to $345 from $300 post a 4Q14 beat and strong outlook for '15. We use a... More
Actavis (ACT) to Adopt 'Allergan' Name
February 18, 2015 7:04 AM ESTActavis plc (NYSE: ACT) today announced that it will adopt a new corporate name Allergan following the anticipated successful completion of the acquisition of Allergan, Inc (NYSE: AGN). The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis' shareholders at its Annual General Meeting later this year.
"The pending... More
Actavis (ACT) Updates on Key Pipeline Program, Potential Market Opportunities
February 18, 2015 6:47 AM ESTActavis (NYSE: ACT) provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.
"Today, we provided an overview of the rationalized, standalone pharmaceutical development pipeline that will power Actavis' ascent into the fastest growing and most dynamic growth pharmaceutical company... More
